Joe Mullings & Dr. Azeem Latib | Tioga & Differentiation

When there has been a therapeutic technology in place for more than a decade and more than 250,000 million procedures performed and yet there are more than 30 product technologies being pursued to solve the same or a similar problem, it informs us that there may not be an optimal solution in the market.

Opportunities in the TMVR market are massive. Previous barriers to more optimal solutions are being lowered and addressed.

French size, geographies for clinical trial activities, AI-based imaging, ease of use and transferrable skills of current solutions that carry over to new and optimized products and solutions offer a far greater patient inclusion criteria than ever before.

In comes Tioga Cardiovascular, a Shifamed company.

Azeem Latib and I discuss the current challenges and opportunities in the mitral valve marketplace for patients.